Brand Name(s): Fludara
CAS nº: 75607-67-9
(flu dah rah been)
About Fludarabine
This new site is dedicated exclusively to fludarabine, also known as fludarabine phosphate.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about fludarabine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also offer you inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total fludarabine experience!
Why is this medication prescribed?
Fludarabine is a cancer (antineoplastic) medication. It is used to treat chronic lymphocytic leukemia (CLL), a type of blood cancer. It is more commonly known by its brand name, Fludara®.
Fludarabine belongs to the group of medicines called antimetabolites. These type of medications work by interfering with the genetic material (DNA) inside the cancer cells and prevent them from further dividing and growing into more cancer cells.
Latest News
Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA
Xanthus Pharmaceuticals, Inc., a privately-held oncology and autoimmune disease drug development...
[more]Protherics and Advancell start Acadra(TM) clinical study in B-cell chronic lymphocytic leukaemia
Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused...
[more]Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG
Xanthus Embarks on Path for Commercialization in the United States
[more]Nipent®, Cytoxan® and Rituxan® Effective for Untreated Poor Risk CLL
Researchers from Ohio State University and the Mayo Clinic have reported that the treatment...
[more]Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Randomized Trial to Evaluate Fludarabine and Rituximab with or without Genasense in Previously...
[more]